A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4363-4368

  Helft, Paul R ^a   Schilsky, Richard L ^a   Hoke, Frank J ^c   Williams, Daphne ^c   Kindler, Hedy L ^a   Sprague, Evie ^a   DeWitte, Mark ^c   Martino, Helen K ^c   Erickson, John ^c   Pandite, Lini ^c   Russo, Mark ^c   Lambert, John M ^b   Howard, Maria ^b   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b IMMUNOGEN INC   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CANTUZUMAB MERTANSINE; LIVER ENZYME; PRODRUG; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; LIVER DISEASE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MAXIMUM TOLERATED DOSE; MAYTANSINE; MICROTUBULES; MIDDLE AGED; NEOPLASMS; PRODRUGS; TIME FACTORS; TRANSAMINASES;

EID: 3042736089     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0088     Document Type: Article

References (11)

1. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31.
2. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 1996;93:8618-23.
3. Johansson C, Nilsson O, Baeckstrom D, Jansson EL, Lindholm L. Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies. Tumour Biol 1991;12:159-70.
4. Baeckstrom D, Hansson GC, Nilsson O, et al. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J Biol Chem 1991;266:21537-47.
5. Blum RH, Kahlert T. Maytansine: a Phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 1978;62:435-8.
6. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev 1978;5:199-207.
7. Chabner BA, Levine AS, Johnson BL, Young RC. Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat Rep 1978;62:429-33.
8. Eagan RT, Ingle JN, Rubin J, Frytak S, Moertel CG. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. J Natl Cancer Inst (Bethesda) 1978;60:93-6.
9. Cabanillas F, Rodriguez V, Hall SW, Burgess MA, Bodey GP, Freireich EJ. Phase I study of maytansine using a 3-day schedule. Cancer Treat Rep 1978;62:425-8.
10. Chari RVJ, Derr SM, Widdison WC, et al. SB408075: a tumor activated prodrug with exceptional activity against colon, pancreatic and lung xenografts. Clin Cancer Res 1999;5:3822s (Suppl).
11. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.